TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05499754

Intervention type: OTHER
Intervention: pLMA: PROSEAL LARYNGEAL MASK, sLMA : SUPREMA LARYNGEAL MASK, I-jel =I-GEL
Description: a SAD was inserted by all anaesthetists participating in the study had at least 3 years experience of airway management and were experienced with both the pLMA, sLMA and I-jel. Inadequate ventilation after two attempts was considered a failed placement, and these patients were excluded, while the practitioner was freed to use an alternative airway device.

Intervention type: OTHER
Intervention: pLMA: PROSEAL LARYNGEAL MASK, sLMA : SUPREMA LARYNGEAL MASK, I-jel =I-GEL
Description: a SAD was inserted by all anaesthetists participating in the study had at least 3 years experience of airway management and were experienced with both the pLMA, sLMA and I-jel. Inadequate ventilation after two attempts was considered a failed placement, and these patients were excluded, while the practitioner was freed to use an alternative airway device.

Intervention type: OTHER
Intervention: pLMA: PROSEAL LARYNGEAL MASK, sLMA : SUPREMA LARYNGEAL MASK, I-jel =I-GEL
Description: a SAD was inserted by all anaesthetists participating in the study had at least 3 years experience of airway management and were experienced with both the pLMA, sLMA and I-jel. Inadequate ventilation after two attempts was considered a failed placement, and these patients were excluded, while the practitioner was freed to use an alternative airway device.
Study: NCT00685204

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milataxel
Description: Milataxel is a liquid that is dosed orally at 60 mg/m2 on Day 1 of a 21 day cycle. If no toxicities of greater than Grade 1 severity occur, patients will receive 75 mg/m2 for the second and subsequent cycles.
Study: NCT00546065

Intervention type: DRUG
Group type: OTHER
Intervention: esomeprazole treatment
Description: concomitant esomeprazole treatment

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: esomeprazole treatment
Description: concomitant esomeprazole treatment
Study: NCT00966524

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endotracheal intubation
Description: Pregraduates medical students will be randomized to perform endotracheal intubation with video-guided feedback (experimental arm) or endotracheal intubation using direct visualization feedback (standard technique).

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endotracheal intubation
Description: Pregraduates medical students will be randomized to perform endotracheal intubation with video-guided feedback (experimental arm) or endotracheal intubation using direct visualization feedback (standard technique).
Study: NCT04824326

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PSAI-CA
Description: The intervention is based on the principles of the teaching of the ancient Greek philosopher Pythagoras. These principals set a basic framework for behavior on the basis of experiential learning and weekly evaluation of the implementation of 12 virtues. The technique is practiced twice a day(before night sleep and in the morning before getting up from bed) and evolves into five successive steps;1)reading of the 12 virtues and diaphragmatic breathing, 2)recall every event og the day,3)third person visualization and self-observation, 4)self-dialogue What have I done wrong?, What have I done right?, What have I omitted that I ought to have done? Endorsement or disapproval of actions according to the 12 virtues and the instructions for a healthy lifestyle, 5) next morning brief revision of the previous night's conclusions and setting of goals for the upcoming day.
Study: NCT00217373

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Fowlpox-CEA(6D)/TRICOM Vaccine
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Interferon Alfa-2b
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant Vaccinia-CEA(6D)-TRICOM Vaccine
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Given SC
Study: NCT00537576

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Low dose LACTIN-V applicator
Description: Low dose LACTIN-V applicator (150 mg LACTIN-V, 5.0 x 10\^8 CFU), administered vaginally once a day for 5 consecutive days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Medium dose LACTIN-V applicator
Description: Medium dose LACTIN-V applicator (300 mg LACTIN-V, 1.0 x 10\^9 CFU), administered vaginally once a day for 5 consecutive days

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High dose LACTIN-V applicator
Description: High dose LACTIN-V applicator (600 mg LACTIN-V, 2.0 x 10\^9 CFU), administered vaginally once a day for 5 consecutive days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Low dose Placebo applicator
Description: Low dose Placebo applicator (150 mg Placebo), administered vaginally once a day for 5 consecutive days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Medium dose Placebo
Description: Medium dose Placebo applicator (300 mg Placebo), administered vaginally once a day for 5 consecutive days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: High dose Placebo applicator
Description: High dose Placebo applicator (600 mg Placebo), administered vaginally once a day for 5 consecutive days
Study: NCT00975611

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amantadine Hydrochloride, USP
Description: amantadine tablets 100 mg. BID for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amantadine Hydrochloride, USP
Description: amantadine 200 mg. tablets BID for 4 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: tablets BID, for 4 weeks
Study: NCT04233112

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin 5 mg
Description: Capsules containing 5mg melatonin will be prepared by Delta Care RX™ Pharmacy. Participants will be asked to take them nightly for one year.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin 5 mg
Description: Capsules containing 5mg melatonin will be prepared by Delta Care RX™ Pharmacy. Participants will be asked to take them nightly for one year.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Osteogenic loading
Description: Osteogenic loading device therapy includes the emulation of impact forces through kinetic chains of natural impact absorption with fixtures that have the ability to capture bone compression data. Participants will be asked to perform osteogenic loading once per week.
Study: NCT04179071

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Savolitinib
Description: Subject will receive savolitinib tablet 600mg orally after a high-fat, high-calorie meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Savolitinib
Description: Subject will receive savolitinib tablet 600mg orally after a high-fat, high-calorie meal.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: Subjects will receive famotidine tablet 40mg orally after an overnight (minimum 8hours) of fasting.
Study: NCT04203680

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: HTK cardioplegic solution
Description: 30 ml/kg of HTK cardioplegic solution at 4°C through an antegrade fashion at an initial perfusion pressure of 80-100 mmHg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: blood cardioplegia
Description: one liter of blood cardioplegia was given with the antegrade route at 30°C, or lower. Blood maintenance cardioplegia was repeated every 30-45mins
Study: NCT04233112

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Osteogenic loading
Description: Osteogenic loading device therapy includes the emulation of impact forces through kinetic chains of natural impact absorption with fixtures that have the ability to capture bone compression data. Participants will be asked to perform osteogenic loading once per week.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mock for Osteogenic Loading
Description: Mock osteogenic loading will occur using the osteogenic loading device therapy includes the emulation of impact forces through kinetic chains of natural impact absorption with fixtures that have the ability to capture bone compression data. Participants will be asked to perform mock osteogenic loading once per week.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Mock for Osteogenic Loading
Description: Mock osteogenic loading will occur using the osteogenic loading device therapy includes the emulation of impact forces through kinetic chains of natural impact absorption with fixtures that have the ability to capture bone compression data. Participants will be asked to perform mock osteogenic loading once per week.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (plant fiber) for melatonin
Description: Capsules containing plant fiber will be prepared by Delta Care RX™ Pharmacy. Participants will be asked to take them nightly for one year.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (plant fiber) for melatonin
Description: Capsules containing plant fiber will be prepared by Delta Care RX™ Pharmacy. Participants will be asked to take them nightly for one year.
Study: NCT06733857

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: VEG2
Description: Participants were provided with a caloric target to place them in a ∼0 to 10% energy surplus, and a protein target of 2 g·kg bm-1·d-1. Participants were instructed to avoid animal products for ≥6 d per wk, focusing their intake on protein-rich non-animal-derived foods (for example, mycoprotein-containing products, pulses, soy). To facilitate reaching protein intake targets, the research team provided participants with mycoprotein-containing vegan products (∼1-2 products per day) to be used as the main protein source for some meals. This group also received 105-g mycoprotein (46-g protein, 10-g carbohydrate, 13-g fat, 348 kcal), 35-g post-training, and 70-g before bed.
Study: NCT00573274

Intervention type: DEVICE
Intervention: Physioflow Impedance
Description: 6 ECG leads applied to the neck and thorax for the duration of surgery (approximately 1 hour).
Study: NCT01895374

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laser treatments

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laser treatments
Study: NCT06733857

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: OMNI2
Description: Participants were provided with a caloric target to place them in a ∼0 to 10% energy surplus, and a protein target of 2 g·kg bm-1·d-1. Participants in OMNI2 were instructed to consume an omnivorous diet, focusing their intake on high-quality animal-derived proteins (that is, meat, milk, yogurt, cheese). To facilitate reaching protein intake targets, the research team provided participants with a weekly supply (∼1-2 products per day) of chicken or beef to be used as the main protein source for some meals. This group also received 59-g supplemental milk protein daily (47-g protein, 2-g carbohydrate, \<1-g fat, 198 kcal) 19.5-g to drink post-training and 39-g to drink before sleep.
Study: NCT01895374

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: amniotic membrane application

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: hydrocolloid application
Study: NCT03324347

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapydog
Description: Presence of a therapydog during a clinical examination in a dental clinic
Study: NCT01045577

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Masitinib
Description: 6 mg/kg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Masitinib
Description: 3 mg/kg/day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching masitinib (3 mg/kg/day and 6 mg/kg/day)
Study: NCT02056015

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [68Ga]MLN6907
Description: IV Administration of \[68Ga\]MLN6907 on Day 1
Study: NCT03775902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicorandil
Description: 20 mg nicorandil (Ikorel, Sanofi Winthrop Industrie; NIC)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicorandil
Description: 20 mg nicorandil (Ikorel, Sanofi Winthrop Industrie; NIC)
Study: NCT01901068

Intervention type: DEVICE
Intervention: MonoMax
Description: Abdominal wall will be closed with MonoMax after an elective primary laparotomy.
Study: NCT03763422

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Oral Administration of Temozolomide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Oral Administration of Temozolomide

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: 50.4 Gy in 28 fractions over 6 weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy
Description: 50.4 Gy in 28 fractions over 6 weeks

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: Surgery
Study: NCT03676855

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: bladder dissection
Description: Comparison between bladder dissection at the beginning of cesarean section For morbidly adherent placenta and between delaying dissection until planning for cesarean hysterectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: bladder dissection
Description: Comparison between bladder dissection at the beginning of cesarean section For morbidly adherent placenta and between delaying dissection until planning for cesarean hysterectomy
Study: NCT00554879

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Needles placed bilaterally on the ears at the auriculotherapy points. Additional needles placed in both index fingers. A third set of needles inserted on both index fingers between LI-1 adn LI-2.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture
Description: Four needles will be placed on the left and right upper shoulder areas. Small circular adhesive tape will be placed in an ear area, but not on the acupuncture points.
Study: NCT02073695

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Operative procedure to fix proximal humeral
Description: Operative fixation by the shoulder team at Torbay Hospital

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Operative procedure to fix proximal humeral
Description: Operative fixation by the shoulder team at Torbay Hospital

Intervention type: DEVICE
Group type: OTHER
Intervention: Neutral Rotation Brace
Description: Performed at the end of the surgical procedure at Torbay Hospital

Intervention type: DEVICE
Group type: OTHER
Intervention: Neutral Rotation Brace
Description: Performed at the end of the surgical procedure at Torbay Hospital

Intervention type: OTHER
Group type: OTHER
Intervention: Physiotherapy review
Description: Physiotherapy review on day of surgery, and post-surgery at 6 weeks, 3 months and 1 year.

Intervention type: OTHER
Group type: OTHER
Intervention: Physiotherapy review
Description: Physiotherapy review on day of surgery, and post-surgery at 6 weeks, 3 months and 1 year.

Intervention type: OTHER
Group type: OTHER
Intervention: Functional outcome forms filled in

Intervention type: OTHER
Group type: OTHER
Intervention: Functional outcome forms filled in

Intervention type: OTHER
Group type: OTHER
Intervention: Postal functional outcome scores
Description: Sent to patient at 9 weeks post surgery

Intervention type: OTHER
Group type: OTHER
Intervention: Postal functional outcome scores
Description: Sent to patient at 9 weeks post surgery

Intervention type: OTHER
Group type: OTHER
Intervention: Post-operative Radiographs
Description: Performed at 6 weeks and 3 months at shoulder clinic appointment at Torbay Hospital

Intervention type: OTHER
Group type: OTHER
Intervention: Post-operative Radiographs
Description: Performed at 6 weeks and 3 months at shoulder clinic appointment at Torbay Hospital
Study: NCT00559650

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Will be standard therapy and placebo versus, Uptitration from 100-600µg/g, intravenous, over maximum 48 hours

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cinaciguat (BAY58-2667)
Description: Will be standard therapy and BAY 58-2667, Uptitration from 100-600µg/g, intravenous, over maximum 48 hours
Study: NCT00310219

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: computed tomography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Study: NCT03093831

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: 560mg administered orally once daily.
Study: NCT00414817

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Automated Phone-Based Refill Reminders
Description: The BREATHE EASY Medication Reminder Program uses interactive voice recognition phone technology to offer timely reminders to patients to refill their ICS medication, educational messages about ICS, and may offer to transfer them to a refill line or to speak with a pharmacist if they have questions.
Study: NCT04886024

Intervention type: OTHER
Intervention: Advanced Glycation End Products (AGEs)
Description: Advanced Glycation End Products (AGEs) releated with energy metabolism, In this study, the possible relationship between the serum levels of Advanced Glycation End Products (AGEs) of endometriosis patients and the disease and its stage is evaluated.

Intervention type: OTHER
Intervention: Advanced Glycation End Products (AGEs)
Description: Advanced Glycation End Products (AGEs) releated with energy metabolism, In this study, the possible relationship between the serum levels of Advanced Glycation End Products (AGEs) of endometriosis patients and the disease and its stage is evaluated.
Study: NCT00738946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intermittent preventive treatment with AQ+ SP
Description: Amodiaquine (10 mg/kg over 3 days) and Sulfadoxine Pyrimethamine (25 mg of sulfadoxine + 1.25 mg of pyrimethamine per kg in a single dose) or placebo administered over 3 rounds of one month interval
Study: NCT03515928

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasonic noise exposure
Description: Group will be exposed to 40kHz ultrasonic noise at 110-120 dB SPL for 15 minutes.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Pure Tone Audiometry
Description: Participants will undergo 2 (pre and post exposure) hearing tests

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Pure Tone Audiometry
Description: Participants will undergo 2 (pre and post exposure) hearing tests
Study: NCT02269566

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HollisterStier
Description: 0.1 ml of 30 AU/ml for Df or Dp, 10 AU/ml for Cat hair, and/or 1:1/10 weight/volume for dog hair/dander 3 injections into an inguinal lymph node

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: 0.1 ml of normal saline 3 injections into an inguinal lymph node
Study: NCT02668081

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Endoscopic papillary balloon dilation
Description: treatment of endoscopic papillary balloon dilation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Endoscopic sphincterotomy
Description: treatment of endoscopic sphincterotomy
Study: NCT04272580

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Control group
Description: No preload was given before spinal anesthesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4 ml/kg group.
Description: 4 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given before spinal anesthesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 8 ml/kg group.
Description: 8 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given before spinal anesthesia.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 12 ml/kg group.
Description: 12 ml/kg compound sodium chloride (0.85% NaCl, 0.03% KCl, and 0.033% CaCl2) was given before spinal anesthesia.
Study: NCT03824379

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Magnesium citrate
Description: magnesium citrate equivalent 20-30 mmol elemental magnesium

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antidiabetic
Description: insulin or oral hypoglycemics
Study: NCT00792792

Intervention type: DEVICE
Intervention: Modulated Imaging
Description: Modulated Imaging Spectroscopy
Study: NCT04190940

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Assessment
Description: Patients will be asked to complete the behavioral assessment before and after their HIFU treatment or on and off their DBS treatment.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral Assessment
Description: Patients will be asked to complete the behavioral assessment before and after their HIFU treatment or on and off their DBS treatment.
Study: NCT03710863

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CM082
Description: Subjects will receive CM082 orally twice daily for two weeks followed by two weeks off in four-week cycles. The starting dose of 25mg BID will be increased by 100% to the maximum dose of 50mg BID.The treatment period is tentatively set at 1 year.
Study: NCT05126394

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound guided serratus anterior plane block
Description: the patients receive local anesthetic (20 ml of Bupivacaine 0.25 %), injected superficial to the serratus muscle under ultrasound guidance.
Study: NCT02235844

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Umbilical Cord Mesenchymal Stem Cells
Study: NCT03997240

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chiropractic Applied Clinical Neuroscience
Description: Chiropractic Applied Clinical Neuroscience makes use of chiropractic care in addition to application of therapies designed to stimulate multisensory reintegration and cerebellar coordination. The multisensory reintegration and cerebellar therapies make use of the body's own sensory receptors as a target, with the purpose of realigning the brain's interpretation of different afferent signals. Observation of motor and autonomic output patterns during and after sensory stimulation afford the clinician real-time feedback, providing for adaptation of the sensory based protocol.